Palladacycle complex DPPE 1.2 was previously reported to inhibit the in vitro and in vivo infection by Leishmania (Leishmania) amazonensis. The aim of the present study was to compare the effect of DPPE 1.2, in association with heat-killed Propionibacterium acnes, on L. (L.) amazonensis infection in two mouse strains, BALB/c and C57BL/6, and to evaluate the immune responses of the treated animals. Foot lesions of L. (L.) amazonensis-infected mice were injected with DPPE 1.2 alone, or associated with P. acnes as an adjuvant. Analysis of T-cell populations in the treated mice and in untreated controls was performed by FACS. Detection of IFN-γ-secreting lymphocytes was carried out by an ELISPOT assay and active TGF-β was measured by means of a double-sandwich ELISA test. The treatment with DPPE 1.2 resulted in a significant reduction of foot lesion sizes and parasite burdens in both mouse strains, and the lowest parasite burden was found in mice treated with DPPE 1.2 plus P. acnes. Mice treated with DPPE 1.2 alone displayed a significant increase of TCD4+ and TCD8+ lymphocytes and IFN-γ secretion which were significantly higher in animals treated with DPPE 1.2 plus P. acnes. A significant reduction of active TGF-β was observed in mice treated with DPPE 1.2 alone or associated with P. acnes. Moreover, DPPE 1.2 associated to P. acnes was non-toxic to treated animals. The destruction of L. (L.) amazonensis by DPPE 1.2 was followed by host inflammatory responses which were exacerbated when the palladacycle complex was associated with P. acnes.
The results show that both homeopathic treatments induced subtle changes in acquired immune anti-viral response regulation. A deeper understanding of the mechanism could elucidate their possible use in influenza epidemiological situations.
In Brazil, homeopathic medicines are prepared according to the Homeopathic Pharmacopeia, regulated by ANVISA. Among several categories of medicines, there is the biotherapic group, which is prepared from etiologic agents. In this study, we developed a biotherapic from influenza A virus, aiming the influenza infection prevention. Influenza is a disease that affects thousands of people worldwide every year, with an important economic impact, what motivates the development of new low cost therapies. The H3N2 biotherapic developed in this study was administered to Balb/c mice to evaluate their immune response to viral specific antigens and behavior (homeopathic proving). Sixty-two 4 weeks old Balb/c mice were divided into five experimental groups (n=14 per group), after approval by the Ethics Committee of Animal Use (Protocol DFBCICB 037) and stimulated daily, blindly, with 1% (v/v) different homeopathic medicines, for a maximum period of 42 days. The tested medicines were: biotherapic 30x prepared from inactivated influenza A virus; biotherapic 30x prepared with infectious influenza A virus; and thymulin 5cH, a thymus hormone. The two control groups were treated with water 30x and nothing (baseline group). After 21 days of treatment, half of the animals from each group was challenged subcutaneously with the viral hemagglutinin antigen (7 mg / 200 mL) and monitored by 21 days further, to evaluate the humoral immune response and general behavior, using an open field device. The remaining animals were evaluated by the same behavioral tests at the end of the first 21 days, as an attempt to define the proving features. After euthanasia, all animals were autopsied and the spleen, lungs, heart and mediastine lymph nodes were weighed. Histometry of the spleen follicles was also made. Histopathological and behavioral analyses showed absence of behavioral effects, however, there was increase of spleen lymphoid follicles diameter in immunized animals treated with thymulin and with the biotherapic prepared from infectious influenza A, when compared to the control group. This experiment is being repeated using flow cytometry to complete the analysis and confirm the results.
Introduction: Biotherapics are medicines prepared from etiologic agents, following Brazilian Homeopathic Pharmacopeia. Influenza is a disease that affects thousands of people worldwide every year, motivating the development of new therapies. Aim: In this study, we developed two biotherapics from live/active influenza A virus, at 12x and 30x, and verified some immune response parameters in mice. Methodology: The biotherapic was administered to male SPF 4 weeks old Balb/c mice. The protocol was approved by the UFRJ Ethics Committee of Animal Use (Protocol DFBCICB 040). Animals were stimulated daily, blindly, with different homeopathic medicines, at 1% (V/V) for a maximum period of 42 days. Three homeopathic medicines were tested: biotherapic 30x containing active influenza A virus; biotherapic 12x containing active influenza A virus; and thymulin 5cH. The experimental groups were: Group A (5 animals) – administration of thymulin 5cH, Group B (5 animals) – administration of biotherapic 30x, Group C (5 animals) – administration of biotherapic 12x, Group D (5 animals) - administration of a water 30x, Group E (5 animals) - administration of a water 12x, Group F (5 animals) - control (without treatment). After 21 days of treatment, all animals were challenged subcutaneously with the viral hemagglutinin antigen at the concentration of 7 ïÂÂÂÂg/200ïÂÂÂÂL and monitored by further 21 days. After euthanasia, all animals were autopsied and the spleen was collected for weight and immunehistochemistry analyses. Additionally, peritoneal washing was done and a “pool†of samples from each group was prepared to be analyzed by flow citometry. Results: Mice treated with biotherapic 30x and thymulin 5cH showed similar profile, different from controls, in which a switch of lymphocytes/phagocytes proportion in the peritoneum was seen, followed by predominance of B1b cells in relation to conventional B and T cells (X2, p=0.005). Regarding to T cell population, in the contrary to control, CD4+ cells were predominant in relation to CD8+ cells (X2, p=0.0001). The immunehistochemistry revealed increase in the number of activated CD11b+ macrophages in spleen (p
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.